Biotech, big pharma not immune from looming ACA issues
Love it or hate it, the Affordable Care Act (ACA) is poised for implementation in 2014, likely creating winners and losers across the health care landscape. To date, the impact on biotechs and pharmas has been relegated to background noise, but the tenor of those discussions is growing as implications of the law pervade every corner of the delivery system.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter